Model design for screening effective Antihyperlipidemic drugs using zebrafish system

Pak J Pharm Sci. 2017 Sep;30(5):1697-1707.

Abstract

The purpose of this paper was to explore a new method for screening lipid-lowering drugs in zebrafish models. The suitable drug concentrations of atorvastatin (ATV), fenofibrate (FEF) and ezetimibe (EZE) were first determined. Then, the serum cholesterol and triglyceride levels were detected in high-fat diet (HFD)-fed zebrafish. The HFD zebrafish models were constructed and the effects of drugs on them were observed by Oil red O staining and fluorescence labeling. Statistical analyses among groups were conducted using SPSS software. The lowest drug concentration (LDC) and the highest (HDC) of ATV, FEF and EZE were 0.3 μM/37.0μM, 1.2μM/3.5μM, and 6.3 μM/26.4μM, respectively, while, the intermediate (IDC) was, in order, 18.5μM, 1.8μM, 13.2μM. The cholesterol and triglyceride levels in HFD-fed zebrafish were increased after 7 weeks fat feeding (p<0.05). Moreover, the levels of triglyceride were significantly decreased after LDC of ATV and FEF treated (p<0.05), but not that of EZE. While, the cholesterol levels were reduced in three groups (p<0.05). Moreover, the 5 dpf high-fat zebrafish model was established successfully and maintained stably for 24h. ATV produced effects in a concentration-dependent manner, while only IDC and HDC of FEF and EZE made effects on this model. Intravascular cholesterol levels were significantly increased after HCD treatment and decreased after drug treated. The high-fat zebrafish model induced by HFD-fed was available and successful, besides, the Oil red O staining may be an available and rapid method for screening lipid-lowering drugs.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Atorvastatin / pharmacology
  • Biomarkers / blood
  • Cholesterol / blood
  • Diet, High-Fat
  • Disease Models, Animal
  • Drug Discovery / methods*
  • Ezetimibe / pharmacology
  • Fenofibrate / pharmacology
  • High-Throughput Screening Assays*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / etiology
  • Hypolipidemic Agents / pharmacology*
  • Lipid Metabolism / drug effects*
  • Male
  • Triglycerides / blood
  • Zebrafish / blood*

Substances

  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Triglycerides
  • Cholesterol
  • Atorvastatin
  • Ezetimibe
  • Fenofibrate